Similarly, EphA3-specific CAR-Ts have been developed based on the EphA3 mAb IIIA4/Ifabotuzumab, and demonstrated toxicity against patient-derived GBM cell lines [76]. This evidence concerns the gene EPHA3 and glioblastoma.